| Project/Area Number |
24790106
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Department of Clinical Research, National Hospital Organization Kure Medical Center |
|---|
Principal Investigator |
OKADA-TSUCHIOKA Mami 独立行政法人国立病院機構(呉医療センター臨床研究部), その他部局等, 研究員 (30517280)
|
|---|
| Project Period (FY) |
2013-02-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | シナプス新生 / 電気けいれん療法 / アストロサイト / thrombospondin-1 / Thrombospondin-1 |
|---|
| Outline of Final Research Achievements |
In this study, I have focused on thrombospondin-1 (TSP-1), an astrocyte-derived synaptogenic factor, as a novel therapeutic target for depression. I have investigated the effects of electroconvulsive seizure (ECS), an animal model of electroconvulsive therapy (ECT), and chronic treatment with antidepressants on the expression of TSP-1 in the adult rat hippocampus. I have revealed that repeated ECS, but not chronic treatment with antidepressants, induced TSP-1 expression partially via the activation of astrocytes. Therefore, TSP-1 is possibly involved in the effects of ECT (Okada-Tsuchioka M et al., 2014).
|
